Keybank National Association OH lessened its stake in Celgene Co. (NASDAQ:CELG) by 1.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 822,619 shares of the biopharmaceutical company’s stock after selling 9,252 shares during the quarter. Celgene makes up approximately 0.7% of Keybank National Association OH’s holdings, making the stock its 29th biggest holding. Keybank National Association OH owned about 0.11% of Celgene worth $119,954,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of CELG. PNC Financial Services Group Inc. raised its stake in shares of Celgene by 13.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 787,046 shares of the biopharmaceutical company’s stock valued at $97,934,000 after purchasing an additional 91,679 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Celgene by 4.3% in the 1st quarter. Legal & General Group Plc now owns 3,587,623 shares of the biopharmaceutical company’s stock valued at $446,406,000 after purchasing an additional 147,263 shares in the last quarter. State Street Corp raised its stake in shares of Celgene by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares in the last quarter. Wedgewood Partners Inc. acquired a new stake in shares of Celgene in the 1st quarter valued at about $23,890,000. Finally, Cypress Capital Group raised its stake in shares of Celgene by 4.8% in the 1st quarter. Cypress Capital Group now owns 35,292 shares of the biopharmaceutical company’s stock valued at $4,392,000 after purchasing an additional 1,602 shares in the last quarter. Institutional investors and hedge funds own 79.74% of the company’s stock.
A number of brokerages have recently issued reports on CELG. Mizuho set a $128.00 target price on shares of Celgene and gave the company a “buy” rating in a research note on Tuesday, December 26th. William Blair restated an “outperform” rating on shares of Celgene in a research note on Friday, October 20th. BidaskClub upgraded shares of Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Citigroup restated a “hold” rating on shares of Celgene in a research note on Friday, December 22nd. Finally, Leerink Swann restated a “buy” rating and issued a $156.00 target price on shares of Celgene in a research note on Friday, October 20th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and twenty have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $131.53.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the business earned $1.58 earnings per share. Celgene’s revenue was up 10.2% compared to the same quarter last year. equities research analysts forecast that Celgene Co. will post 6.69 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2018/01/06/keybank-national-association-oh-has-119-95-million-holdings-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.